Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > ARCHIVE
ARCHIVE
- 10 New Ingredients Added to NHI Price List
September 3, 2001
- Seijo to Tie Up with Fuji Yakuhin, Mine Yakuhin
September 3, 2001
- Time Clock from Development to Approval to Be Shortened to within 5 Years?
September 3, 2001
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
September 3, 2001
- BUSINESS NEWS IN BRIEF
September 3, 2001
- Korosho to Present Healthcare Reform Proposals in September
September 3, 2001
- Takeda, Bayer Decide to Recall Cerivastatin in Japan
September 3, 2001
- Alendronate to Change Market for Osteoporosis
August 27, 2001
- REGULATORY NEWS IN BRIEF -1-
August 27, 2001
- Genzyme to Switch to Quatro Test for Maternal Serum Testing
August 27, 2001
- Contract MRs Are Being Rapidly Accepted: Apo Plus Station President
August 27, 2001
- Korosho to Start Model Project to Set Up Network of Electronic Medical Charts
August 27, 2001
- BULLETIN
August 27, 2001
- BUSINESS NEWS IN BRIEF -1-
August 27, 2001
- Errors in Medical Bills Related to Patients' ID Increasing
August 27, 2001
- REGULATORY NEWS IN BRIEF -2-
August 27, 2001
- BUSINESS NEWS IN BRIEF -2-
August 27, 2001
- Number of Long-term Care Beds Up to 5,837
August 27, 2001
- CORPORATE ROUNDUP NEWS IN BRIEF
August 27, 2001
- IFN Alphacon-1 Recommended for Approval
August 27, 2001
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…